One platform. Two species.
A single bioelectronic platform targeting the stellate ganglion. Developed first for human PTSD, extended to veterinary medicine.
The common core
002 / 005One anatomical target. One drug-free mechanism.
Stimalia's platform centres on precise, drug-free neuromodulation of the stellate ganglion, the autonomic relay that sits downstream of the amygdala. By interrupting the feedback loop that keeps the body's alarm response engaged, the same core technology applies wherever chronic threat response drives disease. An intellectual property estate spanning more than 300 patent claims protects the platform across species.
Two paths to market
003 / 005The same implant, purpose built for each species.
TraumaTone
The world's first percutaneous bioelectronic implant designed for PTSD. Stimalia's lead program and the company's primary focus.
CalmTone Vet
The same platform applied to companion animals, starting with trauma and chronic stress related behavioural disorders in dogs. A shorter regulatory path, outside human premarket frameworks, targeting market entry around 2028 to 2029.
Platform value
004 / 005Why two species strengthen one company.
Faster validation
The veterinary program generates real world evidence of the platform on a shorter timeline, informing the human path.
Expanded market
Two addressable markets from one technology base and one shared IP estate.
Focus preserved
The veterinary unit is ring-fenced and helps fund the platform, while human PTSD remains the company's priority.
One asset
A single unified platform and IP estate, built toward one strategic outcome.
Invest in the platform.
Stimalia is building one bioelectronic platform with two paths to market. We work with investors and strategic partners who back platform companies.
TraumaTone and CalmTone Vet are investigational and under development. Not available for sale. Statements on this page describe development programs and are not therapeutic claims.